Agentix (AGTX) EBITDA Margin (2015 - 2021)
Agentix's (AGTX) quarterly EBITDA Margin came in at 19685.89% in Q3 2021, down 248.6% on a QoQ basis from 5647.2% in Q1 2017.
Agentix (AGTX) EBITDA Margin (2015 - 2021) Analysis & Trends
Agentix (AGTX) has 4 years of EBITDA Margin data on file, last reported at 19685.89% in Q3 2021.
- Quarterly EBITDA Margin changed N/A year-over-year to 19685.89% in Q3 2021, while the trailing twelve-month figure through Mar 2023 was 110625.48% (changed N/A YoY) and the FY2022 annual result came in at 211825.08%, changed N/A from the prior year.
- EBITDA Margin slipped to 19685.89% in Q3 2021, from 5647.2% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 5647.2% in Q1 2017 to a low of 19685.89% in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2021 | -19,685.89% |
| Feb 28, 2017 | -5,647.20% |
| Aug 31, 2016 | -13,012.54% |
| May 31, 2016 | -1,438.57% |
| Feb 29, 2016 | 2.29% |
| Nov 30, 2015 | -2.33% |
| Aug 31, 2015 | -145.27% |
| May 31, 2015 | -137.20% |